SCHEMBL6778429

SCHEMBL6778429

CCOc1ccccc1C(=O)N(Cc1ccccc1-c1ccccc1)c1ccncc1

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.50
▸ LTB4R2 Q9NPC1 7/20 0.49
▸ ALDH1A1 P00352 2/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ RXFP1 Q9HBX9 1/20 0.43
▸ PLA2G1B P04054 1/20 0.42
▸ PDK1 Q15118 1/20 0.40
▸ HCRTR1 O43613 1/20 0.39
▸ HCRTR2 O43614 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ AGTR1 P30556 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A4 P31645 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6783999 0.89 PTGER1 (0.47) LTB4R2PLA2G1BPDK1
SCHEMBL6775891 0.89 PDK1 (0.47) MAPTLTB4R2ALDH1A1L3MBTL1PDK1
SCHEMBL6781088 0.89 ALDH1A1 (0.45) MAPTLTB4R2ALDH1A1L3MBTL1PDK1
SCHEMBL6778305 0.86 LTB4R2 (0.52) MAPTLTB4R2ALDH1A1L3MBTL1KDM4E
SCHEMBL6783823 0.85 ALDH1A1 (0.47) MAPTALDH1A1L3MBTL1RXFP1HCRTR1
SCHEMBL6780805 0.83 KMT2A (0.47) MAPTLTB4R2L3MBTL1LMNA
SCHEMBL6780224 0.83 OXTR (0.51) MAPTALDH1A1L3MBTL1
SCHEMBL6785514 0.81 LTB4R2 (0.46) LTB4R2ALDH1A1PDK1KDM4E
SCHEMBL6780767 0.78 ALDH1A1 (0.46) MAPTALDH1A1L3MBTL1PDK1KDM4E
SCHEMBL6774316 0.77 ALDH1A1 (0.51) MAPTLTB4R2ALDH1A1PDK1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US claimed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US claimed
US-6780883-B2 ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS WARNER-LAMBERT COMPANY 2004-08-24 — — US disclosed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein CETP, MTTP, LCAT MAPT 3054/4885LTB4R2 1613/4885ALDH1A1 646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback